CY1116297T1 - Ενωσεις αρυλοτριαζολιου με αντικαρκινικη δραστικοτητα - Google Patents

Ενωσεις αρυλοτριαζολιου με αντικαρκινικη δραστικοτητα

Info

Publication number
CY1116297T1
CY1116297T1 CY20151100441T CY151100441T CY1116297T1 CY 1116297 T1 CY1116297 T1 CY 1116297T1 CY 20151100441 T CY20151100441 T CY 20151100441T CY 151100441 T CY151100441 T CY 151100441T CY 1116297 T1 CY1116297 T1 CY 1116297T1
Authority
CY
Cyprus
Prior art keywords
arylotrizoli
units
cancer activity
hsp90
inhibition
Prior art date
Application number
CY20151100441T
Other languages
Greek (el)
English (en)
Inventor
Giuseppe Giannini
Walter Cabri
Loredana Vesci
Maria Luisa Cervoni
Claudio Pisano
Maurizio Taddei
Serena Ferrini
Original Assignee
Sigma-Tau Research Switzerland S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Research Switzerland S.A. filed Critical Sigma-Tau Research Switzerland S.A.
Publication of CY1116297T1 publication Critical patent/CY1116297T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CY20151100441T 2010-12-20 2015-05-15 Ενωσεις αρυλοτριαζολιου με αντικαρκινικη δραστικοτητα CY1116297T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10195949 2010-12-20
EP11805449.3A EP2655345B1 (en) 2010-12-20 2011-12-13 Aryl triazole compounds with antitumoural activity

Publications (1)

Publication Number Publication Date
CY1116297T1 true CY1116297T1 (el) 2017-02-08

Family

ID=43901588

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100441T CY1116297T1 (el) 2010-12-20 2015-05-15 Ενωσεις αρυλοτριαζολιου με αντικαρκινικη δραστικοτητα

Country Status (16)

Country Link
US (1) US9302998B2 (enExample)
EP (1) EP2655345B1 (enExample)
JP (1) JP2014501232A (enExample)
AR (1) AR084361A1 (enExample)
CY (1) CY1116297T1 (enExample)
DK (1) DK2655345T3 (enExample)
ES (1) ES2536980T3 (enExample)
HR (1) HRP20150450T1 (enExample)
HU (1) HUE025697T2 (enExample)
ME (1) ME02144B (enExample)
PL (1) PL2655345T3 (enExample)
PT (1) PT2655345E (enExample)
RS (1) RS53966B1 (enExample)
SI (1) SI2655345T1 (enExample)
SM (1) SMT201500115B (enExample)
WO (1) WO2012084602A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101676208B1 (ko) * 2012-09-17 2016-11-14 에프. 호프만-라 로슈 아게 트라이아졸 카복스아미드 유도체
CN103275023B (zh) * 2013-06-08 2015-10-07 浙江工业大学 1-芳基-1,2,3-三氮唑类化合物及其制备和应用
CN107540624B (zh) * 2016-06-29 2020-06-16 广州市恒诺康医药科技有限公司 热休克蛋白抑制剂及其制备方法和应用
WO2018081814A1 (en) * 2016-10-31 2018-05-03 University Of Kansas Grp94 selective inhibitors and uses thereof
WO2019040869A1 (en) * 2017-08-25 2019-02-28 The Trustees Of Columbia University In The City Of New York INHIBITORS OF IMPORTS OF PURINE IN PARASITES AND USES OF THESE INHIBITORS
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN110590686B (zh) * 2019-10-31 2022-10-25 重庆大学 一种氮杂糖基1,2,3-三氮唑核苷化合物及其制备方法和应用
WO2021137665A1 (ko) * 2019-12-30 2021-07-08 이화여자대학교 산학협력단 Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물 및 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10315570A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Triazolderivate
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
GB0323810D0 (en) 2003-10-10 2003-11-12 Cancer Rec Tech Ltd Pyridothiophene compounds
ES2594874T3 (es) 2004-11-18 2016-12-23 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad de HSP90
WO2006109846A1 (ja) 2005-04-06 2006-10-19 Takeda Pharmaceutical Company Limited トリアゾール誘導体およびその用途
JP2006306755A (ja) * 2005-04-27 2006-11-09 Nippon Kayaku Co Ltd 新規なピラゾール誘導体とそれを有効成分とするhsp90阻害剤
JP5149177B2 (ja) * 2005-07-25 2013-02-20 シンタ ファーマシューティカルズ コーポレーション 増殖性疾患の治療のための、チューブリンポリマー化の1,2,3−トリアゾール系抑制剤
CA2664852A1 (en) * 2006-10-03 2008-04-10 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of resorcinol derivatives
NZ579403A (en) * 2007-02-08 2012-03-30 Synta Pharmaceuticals Corp Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer
WO2009115486A1 (en) 2008-03-18 2009-09-24 Glaxo Group Limited Triazole amide derivatives for use in therapy
LT5623B (lt) 2008-04-30 2010-01-25 Biotechnologijos Institutas, , 5-aril-4-(5-pakeistieji 2,4-dihidroksifenil)-1,2,3-tiadiazolai kaip hsp90 šaperono slopikliai ir tarpiniai junginiai jiems gauti
WO2009139916A1 (en) 2008-05-16 2009-11-19 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate hsp90 activity
US9126953B2 (en) 2008-08-08 2015-09-08 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
EP2323737A2 (en) 2008-08-08 2011-05-25 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity

Also Published As

Publication number Publication date
PL2655345T3 (pl) 2015-07-31
EP2655345A1 (en) 2013-10-30
SMT201500115B (it) 2015-07-09
US9302998B2 (en) 2016-04-05
RS53966B1 (sr) 2015-08-31
WO2012084602A1 (en) 2012-06-28
ME02144B (me) 2015-10-20
EP2655345B1 (en) 2015-02-18
AR084361A1 (es) 2013-05-08
HUE025697T2 (en) 2016-04-28
US20140329812A1 (en) 2014-11-06
PT2655345E (pt) 2015-06-09
DK2655345T3 (en) 2015-05-04
ES2536980T3 (es) 2015-06-01
JP2014501232A (ja) 2014-01-20
SI2655345T1 (sl) 2015-06-30
HRP20150450T1 (hr) 2015-06-05

Similar Documents

Publication Publication Date Title
CY1123649T1 (el) Παραγωγα ιμιδαζολινης, μεθοδοι παρασκευης αυτων και εφαρμογες αυτων στην ιατρικη
SA522441701B1 (ar) مشتقات كينوكسالين كعقاقير مضادة للسرطان
EA201170139A1 (ru) 5-фенилизоксазол-3-карбоксамиды с противоопухолевыми активностями, модулирующие hsp90
CY1125772T1 (el) Μακροκυκλικες ενωσεις για τη θεραπευτικη αντιμετωπιση νοσων
CY1116100T1 (el) Παραγωγα πυριμιδινονης, η παρασκευη τους και η φαρμακευτικη τους χρηση
CY1119387T1 (el) Τριαζολοπυραζινες ως αναστολεις brd4 για χρηση στην αντιμετωπιση καρκινου
BRPI0610850A2 (pt) derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
CY1118899T1 (el) Ενωσεις ενεδιυνης, συζευγματα εξ’ αυτων, και χρησεις και μεθοδοι δια τουτων
CY1117580T1 (el) Νεα ετεροκυκλικα παραγωγα και η χρηση τους στη θεραπεια νευρολογικων διαταραχων
Helgren et al. The synthesis, antimalarial activity and CoMFA analysis of novel aminoalkylated quercetin analogs
CY1121137T1 (el) Φαρμακευτικα σκευασματα που περιλαμβανουν ανταγωνιστες ccr3
CY1113269T1 (el) Παραγωγα ινδαζολυλ αμιδιου για τη θεραπευτικη αγωγη διαταραχων διαμεσολαβουμενων υπο υποδοχεα γλυκοκορτικοειδων
CY1121910T1 (el) Φαρμακευτικο παρασκευασμα που περιεχει παραγωγο διυδροκιναζολινης με αντιϊικη δραση
BR112016007622A2 (pt) composto, composição farmacêutica, conjugado de ligante-droga, e, método para tratar câncer
CY1119252T1 (el) Νεα παραγωγα 1-βενζυλο-3 -υδροξυμεθυλινδαζολης και χρηση αυτων στη θεραπεια νοσων που βασιζονται στην εκφραση των cx3cr1 και ρ40
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
CY1117996T1 (el) Genz 112638 για την θεραπευτικη αγωγη της νοσου gaucher ή fabry σε θεραπεια συνδυασμου
CY1111903T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου με αναλγητικη δραση
CY1117909T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει ολμεσαρτανη μεδοξομιλη και ροσουβαστατινη ή το αλας της
BR112015004501A2 (pt) derivado de ácido hialurônico tendo aminoácidos e grupos esterila introduzidos no mesmo
PH12014500249A1 (en) New thio derivatives bearing lactams as potent hdac inhibitors and their uses as medicaments
CY1114737T1 (el) Παραγωγα κινοξαλινδιονης
CY1115590T1 (el) Σουλφοξιμινυποκατεστημενα παραγωγα ανιλινοπυριμιδινης ως cdk-αναστολεις, η παραγωγη αυτων και η χρηση αυτων ως φαρμακευτικα μεσα
CY1116683T1 (el) Φαρμακο το οποιο περιεχει ενα παραγωγο καρβοστυριλιου και δονεπεζιλη για τη θεραπεια της νοσου alzheimer
CY1114521T1 (el) Ενωσεις βενζαμιδιου χρησιμες ως αναστολεις αποακετυλασων ιστονων